Metformin Hydrochloride is a biguanide antidiabetic. Glucomet® is given orally for the treatment of type 2 diabetes mellitus. Glucomet® does not stimulate insulin release and requires that some insulin be present in order to exert its antidiabetic effect. Possible mechanisms of action include delay in the absorption of glucose from the gastro-intestinal tract, an increase in insulin sensitivity and glucose uptake into cells, and inhibition of hepatic gluconeogenesis. Glucomet® does not produce hypoglycaemia in either normal subjects or patients with type 2 diabetes and does not cause hyperinsulinaemia.


Metformin Hydrochloride is slowly and incompletely absorbed from the gastro-intestinal tract; the absolute bioavailability of a single 500mg dose is reported to be about 50 to 60%, although this is reduced somewhat if taken with food. Following absorption plasma protein binding is negligible, and it is excreted unchanged in the urine. The plasma elimination half-life is reported to range from about 2 to 6 hours after oral administration.


Glucomet® as monotherapy is indicated as an adjunct to diet and excercise in the management of type 2 diabetes. Glucomet® XR 500 Extended Release Tablet is specially made to release the drug slowly in the body and therefore is different from many other types of tablets containing metformin. Glucomet® may be used in combination with sulphonylureas, thiazolidinediones and insulin to improve glycaemic control in adults.


Dosage of Glucomet® must be individualised on the basis of effectiveness and tolerance.
In general, clinically significant responses are not seen at doses below 1500mg per day.
Glucomet® XR 500 Tablets should be swallowed whole with a glass of water and should not be chewed.  A lower starting dose with gradual escalation is recommended to minimise gastrointestinal symptoms. The usual starting dose is 500mg twice a day or 850mg once a day given with meals. This is gradually increased to 2000mg to 3000mg daily in 2-3 divided doses.


Glucomet® is contraindicated in:
 Patients with renal disease or renal dysfunction.
 Patients with Known hypersensitivity to metformin.
 Acute or chronic metabolic acidosis with or without coma.
Diabetic ketoacidosis should be treated with insulin.


Biguanides are inappropriate for patients with diabetic coma and ketoacidosis, or for those with severe infection, trauma, or other severe conditions where the biguanide is unlikely to control the hyperglycaemia; insulin should be administered in such situations.  Glucomet® should also not be given to patients with heart failure, recent myocardial infarction, dehydration, alcoholism, or any other condition likely to predispose to lactic acidosis.

Adverse Effects:
Gastro-intestinal adverse effects include anorexia, nausea and diarrhoea. Patients may experience a metallic taste and there may be weight loss. Absorption of various substances including vitamin B12 may be impaired. Lactic acidosis, sometimes, fatal, has occurred.

Acute poisoning may lead to the development of lactic acidosis and calls for intensive supportive therapy.

Use of Glucomet® with other drugs that lower blood glucose concentrations increases the risk of hypoglycaemia, while drugs that increase blood glucose may reduce the effect of Glucomet® therapy.

Alcohol may increase the risk of lactic acidosis as well as of hypoglycaemia. Care should be taken if Glucomet® is given with drugs that may impair renal function.

Store in a dry place below 25ºC. Protect from light. Keep all medicines out of the reach of children.

Prescription Only Medicine (POM)
®Regd. TM   Ref. No.: INS057/06.09

  • Glucomet® XR 500 Tablets:

    PresentationWhite, oblong shaped, biconvex tablet embossed 500 on one side and plain on the other side. Each Extended Release Tablet Contains: Metformin Hydrochloride USP 500mg.Pack size - 28's (2x14's)

  • Glucomet® 500 Tablets

    PresentationWhite, circular, biconvex, film coated tablet embossed 'GLUCOMET' on one side and '500' on the other side. Each film coated tablet contains: Metformin Hydrochloride BP 500mg.Pack size - 28's (2x14's)

  • Glucomet® 850 Tablets

    PresentationWhite, oblong-shaped, biconvex, film coated tablet embossed 'COSMOS' on one side and a breakline on the other side. Each film coated tablet contains: Metformin Hydrochloride BP 850mg. Pack size - 28's (2x14's) & 56's (4x14's)